{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:36:48Z","timestamp":1793065008412,"version":"4.5.0"},"reference-count":160,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontierspartnerships.org"],"crossmark-restriction":true},"short-container-title":["J. pharm. pharm. sci."],"abstract":"<jats:p>Inflammation is a culprit in many conditions affecting millions of people worldwide. A plethora of studies has revealed that inflammation and inflammatory mediators such as cytokines and chemokines are associated with altered expression and activity of various proteins such as those involved in drug metabolism, specifically cytochrome P450 enzymes (CYPs). Emphasis of most available reports is on the inflammation-induced downregulation of CYPs, subsequently an increase in their substrate concentrations, and the link between the condition and the inflammatory mediators such as interleukin-6 and tumor necrosis factor alpha. However, reports also suggest that inflammation influences expression and\/or activity of other proteins such as those involved in the drug-receptor interaction. These multifaced involvements render the clinical consequence of the inflammation unexpected. Such changes are shown in many inflammatory conditions including rheumatoid arthritis, Crohn\u2019s disease, acute respiratory illnesses as well as natural processes such as aging, among others. For example, some commonly used cardiovascular drugs lose their efficacy when patients get afflicted with inflammatory conditions such as rheumatoid arthritis and Crohn\u2019s disease. Interestingly, this is despite increased concentration subsequent to reduced clearance. The observation is attributed to a simultaneous reduction in the expression of target receptor proteins such as the calcium and potassium channel and \u03b2-adrenergic receptor as well as the metabolic enzymes. This narrative review summarizes the current understanding and clinical implications of the inflammatory effects on both CYPs and drug-receptor target proteins.<\/jats:p>","DOI":"10.3389\/jpps.2023.11137","type":"journal-article","created":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T23:11:22Z","timestamp":1675638682000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition"],"prefix":"10.3389","volume":"26","author":[{"given":"Yasmeen El Hajj","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhman","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fakhreddin","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif Hanafy","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"B1","first-page":"292","article-title":"Drug disease interactions: Role of inflammatory mediators in depression and variability in antidepressant drug response","volume":"9","author":"Kulmatycki","year":"2006","journal-title":"J Pharm Pharm Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.18433\/j36p47","article-title":"Drug disease interactions: Role of inflammatory mediators in pain and variability in analgesic drug response","volume":"10","author":"Kulmatycki","year":"2008","journal-title":"J Pharm Pharm Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/bmj.2.6047.1324-b","article-title":"Plasma propranolol levels in coeliac disease and Crohn's disease","volume":"2","author":"Schneider","year":"1976","journal-title":"Br Med J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/cyto.2000.0827","article-title":"Therapeutic relevance of altered cytokine expression","volume":"14","author":"Kulmatycki","year":"2001","journal-title":"Cytokine"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1467538","article-title":"The regulation of inflammation by innate and adaptive lymphocytes","volume":"2018","author":"Cronkite","year":"2018","journal-title":"J Immunol Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/ni.3790","article-title":"A guiding map for inflammation","volume":"18","author":"Netea","year":"2017","journal-title":"Nat Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: Mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.biopha.2017.05.055","article-title":"Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy","volume":"92","author":"Alam","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1758-5996-5-31","article-title":"Chronic inflammation role in the obesity-diabetes association: A case-cohort study","volume":"5","author":"Luft","year":"2013","journal-title":"Diabetology Metab Syndr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10741-006-9196-2","article-title":"Systemic inflammation in heart failure - the whys and wherefores","volume":"11","author":"Yndestad","year":"2006","journal-title":"Heart Fail Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.molcel.2014.03.030","article-title":"Stress, inflammation, and defense of homeostasis","volume":"54","author":"Chovatiya","year":"2014","journal-title":"Mol Cel"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0132001","DOI":"10.1371\/journal.pone.0132001","article-title":"Association of DNA methylation with acute mania and inflammatory markers","volume":"10","author":"Sabunciyan","year":"2015","journal-title":"PLoS ONE"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1038\/tp.2013.94","article-title":"Gene expression profiling by mRNA sequencing reveals increased expression of immune\/inflammation-related genes in the hippocampus of individuals with schizophrenia","volume":"3","author":"Hwang","year":"2013","journal-title":"Transl Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/nature01320","article-title":"Points of control in inflammation","volume":"420","author":"Nathan","year":"2002","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000054274","article-title":"Decrease in brain cytochrome P450 enzyme activities during infection and inflammation of the central nervous system","volume":"8","author":"Monshouwer","year":"2000","journal-title":"Neuroimmunomodulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"104499","DOI":"10.1016\/j.neuint.2019.104499","article-title":"Role of NF-\u03baB in cytochrome P450 epoxygenases down-regulation during an inflammatory process in astrocytes","volume":"129","author":"Navarro-Mabarak","year":"2019","journal-title":"Neurochem Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10741-008-9104-z","article-title":"Biology of TNF\u03b1 and IL-10, and their imbalance in heart failure","volume":"14","author":"Kaur","year":"2009","journal-title":"Heart Fail Rev"},{"key":"B19","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/nejmra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"New Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fimmu.2018.00089","article-title":"The role of cytochromes P450 in infection","volume":"9","author":"Stavropoulou","year":"2018","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fphar.2012.00008","article-title":"Immunological response as a source to variability in drug metabolism and transport","volume":"3","author":"Christensen","year":"2012","journal-title":"Front Pharmacol"},{"key":"B23","first-page":"e1","article-title":"Treatments considered for COVID-19","volume":"62","year":"2020","journal-title":"Med Lett Drugs Ther"},{"key":"B24","article-title":"Clopidogrel therapy and CYP2C19 genotype","author":"Dean","year":"2012","journal-title":"Med Genet Summ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.3892\/mmr.2018.8377","article-title":"Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (-806 C>T) alleles among an Iranian population of different ethnicities","volume":"17","author":"Dehbozorgi","year":"2018","journal-title":"Mol Med Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00228-002-0423-z","article-title":"Allele and genotype frequencies of polymorphic DCP1, CETP, ADRB2, and HTR2A in the Egyptian population","volume":"58","author":"Hamdy","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/jhep.2003.50393","article-title":"Sex is a major determinant of CYP3A4 expression in human liver","volume":"38","author":"Wolbold","year":"2003","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1210\/me.2006-0007","article-title":"Growth hormone regulation of sex-dependent liver gene expression","volume":"20","author":"Waxman","year":"2006","journal-title":"Mol Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1530\/eje.0.1340287","article-title":"Gender differences in secretory activity of the human somatotropic (growth hormone) axis","volume":"134","author":"Veldhuis","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol Pharmaceutics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Disposition"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/jps.10381","article-title":"Disease-drug interaction: Reduced response to propranolol despite increased concentration in the rat with inflammation","volume":"92","author":"Guirguis","year":"2003","journal-title":"J Pharm Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1124\/dmd.104.002360","article-title":"Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: An alternative approach to the use of an animal model of inflammation for pharmacokinetic studies","volume":"33","author":"Ling","year":"2005","journal-title":"Drug Metab Disposition"},{"key":"B34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/chir.530060508","article-title":"Influence of endotoxin on the stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil in the rat","volume":"6","author":"Laethem","year":"1994","journal-title":"Chirality"},{"key":"B35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1742-7843.2009.00405.x","article-title":"The effect of infliximab on hepatic cytochrome p450 and pharmacokinetics of verapamil in rats with pre-adjuvant arthritis: A drug-disease and drug-drug interaction","volume":"105","author":"Ling","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/sj.bjp.0705202","article-title":"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart","volume":"139","author":"Sattari","year":"2003","journal-title":"Br J Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1365-2125.2011.04019.x","article-title":"Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity","volume":"72","author":"Sanaee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2125.2000.00314.x","article-title":"Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis","volume":"50","author":"Mayo","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"B39","first-page":"240","article-title":"Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis","volume":"23","author":"Piquette-Miller","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"B40","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/BF02028122","article-title":"Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats","volume":"37","author":"Piquette-Miller","year":"1992","journal-title":"Agents and Actions"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3109\/03602539709002246","article-title":"Regulation of cytochromes P450 during inflammation and infection","volume":"29","author":"Morgan","year":"1997","journal-title":"Drug Metab Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1172\/jci117582","article-title":"Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism","volume":"94","author":"Shedlofsky","year":"1994","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1124\/dmd.107.018051","article-title":"Regulation of hepatic drug-metabolizing enzyme genes by toll-like receptor 4 signaling is independent of toll-interleukin 1 receptor domain-containing adaptor protein","volume":"36","author":"Ghose","year":"2007","journal-title":"Drug Metab Disposition"},{"key":"B44","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fphar.2016.00456","article-title":"Pregnane X receptor (PXR)-mediated gene repression and cross-talk of PXR with other nuclear receptors via coactivator interactions","volume":"7","author":"Pavek","year":"2016","journal-title":"Front Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1124\/mol.117.110155","article-title":"Pxr: More than just a master xenobiotic receptor","volume":"93","author":"Oladimeji","year":"2018","journal-title":"Mol Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1124\/jpet.104.076141","article-title":"The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice","volume":"312","author":"Teng","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/j.1471-4159.2004.02449.x","article-title":"A novel lipopolysaccharide-modulated Jun binding repressor in intron 2 of CYP2E1","volume":"89","author":"Tindberg","year":"2004","journal-title":"J Neurochem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"17882","DOI":"10.1074\/jbc.m601302200","article-title":"Role of NF-\u03baB in regulation of PXR-mediated gene expression","volume":"281","author":"Gu","year":"2006","journal-title":"J Biol Chem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fj.02-0195fje","article-title":"Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: Molecular mechanism and transcription factors involved","volume":"16","author":"Jover","year":"2002","journal-title":"FASEB J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"S447","DOI":"10.1097\/00003246-199310001-00006","article-title":"Role of tumor necrosis factor-alpha in disease states and inflammation","volume":"21","author":"Strieter","year":"1993","journal-title":"Crit Care Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/231210","article-title":"Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C","volume":"2012","author":"Neuman","year":"2012","journal-title":"Int J Hepatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1054\/jcaf.2002.127773","article-title":"Plasma levels of TNF-\u03b1 and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure","volume":"8","author":"Frye","year":"2002","journal-title":"J Card Fail"},{"key":"B53","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1124\/dmd.114.060962","article-title":"A systematic comparison of the impact of inflammatory signaling on absorption, distribution, metabolism, and excretion gene expression and activity in primary human hepatocytes and HepaRG cells","volume":"43","author":"Klein","year":"2015","journal-title":"Drug Metab Disposition"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e00027","DOI":"10.1002\/prp2.27","article-title":"Selective effects of a therapeutic protein targeting tumor necrosis factor-alpha on cytochrome P450 regulation during infectious colitis: Implications for disease-dependent drug-drug interactions","volume":"2","author":"Nyagode","year":"2014","journal-title":"Pharmacol Res Perspect"},{"key":"B55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fcell.2019.00091","article-title":"TNFR1 and TNFR2 in the control of the life and death balance of macrophages","volume":"7","author":"Wajant","year":"2019","journal-title":"Front Cel Dev Biol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s10787-007-0013-x","article-title":"Role of nitric oxide in inflammatory diseases","volume":"15","author":"Sharma","year":"2007","journal-title":"Inflammopharmacol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"11147","DOI":"10.1073\/pnas.90.23.11147","article-title":"Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants","volume":"90","author":"Khatsenko","year":"1993","journal-title":"Proc Natl Acad Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab Disposition"},{"key":"B59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/01.cir.90.1.375","article-title":"Induction of nitric oxide synthase gene by interleukin-1\u03b2 in cultured rat cardiocytes","volume":"90","author":"Tsujino","year":"1994","journal-title":"Circulation"},{"key":"B60","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/s0091-6749(98)70118-6","article-title":"Biologic activities of IL-1 and its role in human disease","volume":"102","author":"Essayan","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/s0006-2952(97)00226-8","article-title":"Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1\u03b2 and endotoxin in primary rat hepatocytes","volume":"54","author":"Sewer","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.dmpk.2020.02.001","article-title":"Interleukin-1\u03b2 and tumor necrosis factor-\u03b1 affect cytochrome P450 expression in cynomolgus macaque hepatocytes","volume":"35","author":"Uno","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"key":"B63","doi-asserted-by":"publisher","first-page":"930","DOI":"10.2174\/138920012802138642","article-title":"Effects of interleukin 1\u03b2 (IL-1\u03b2) and IL-1\u03b2\/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture","volume":"13","author":"J Dickmann","year":"2012","journal-title":"Curr Drug Metab"},{"key":"B64","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1124\/dmd.32.3.359","article-title":"Kupffer cell-mediated il-2 suppression of cyp3a activity in human hepatocytes","volume":"32","author":"Sunman","year":"2004","journal-title":"Drug Metab Disposition"},{"key":"B65","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2174\/138920012802138589","article-title":"De-risking bio-therapeutics for possible drug interactions using cryopreserved human hepatocytes","volume":"13","author":"Dallas","year":"2012","journal-title":"Curr Drug Metab"},{"key":"B66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0006-2952(92)90047-m","article-title":"Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat","volume":"44","author":"Chen","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291x(92)90684-d","article-title":"Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells","volume":"184","author":"Fukuda","year":"1992","journal-title":"Biochem Biophysical Res Commun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12891-015-0516-3","article-title":"Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from rheumatoid arthritis patients","volume":"16","author":"Santos Savio","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"B69","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40360-018-0221-6","article-title":"Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients","volume":"19","author":"Molanaei","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"113725","DOI":"10.1016\/j.bcp.2019.113725","article-title":"MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation","volume":"171","author":"Kugler","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrg3965","article-title":"Towards a molecular understanding of microRNA-mediated gene silencing","volume":"16","author":"Jonas","year":"2015","journal-title":"Nat Rev Genet"},{"key":"B72","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.dmpk.2014.09.004","article-title":"Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4","volume":"30","author":"Mimura","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"key":"B73","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0006-2952(98)00372-4","article-title":"Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy","volume":"57","author":"Elkahwaji","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"361","DOI":"10.18433\/j30300","article-title":"Effect of inflammation on molecular targets and drug transporters","volume":"15","author":"Hanafy","year":"2012","journal-title":"J Pharm Pharm Sci"},{"key":"B75","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd4461","article-title":"What do drug transporters really do?","volume":"14","author":"Nigam","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.xphs.2018.09.024","article-title":"Dysregulation of mucosal membrane transporters and drug-metabolizing enzymes in ulcerative colitis","volume":"108","author":"Erdmann","year":"2019","journal-title":"J Pharm Sci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"105264","DOI":"10.1016\/j.ejps.2020.105264","article-title":"Rheumatoid arthritis downregulates the drug transporter OATP1B1: Fluvastatin as a probe","volume":"146","author":"Caris","year":"2020","journal-title":"Eur J Pharm Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40262-016-0462-8","article-title":"Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis","volume":"56","author":"Lee","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"B79","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1254\/jphs.13141fp","article-title":"Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations","volume":"124","author":"Kawauchi","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"B80","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1124\/dmd.108.023630","article-title":"Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-\u03b1 or interleukin-6","volume":"37","author":"Vee","year":"2008","journal-title":"Drug Metab Disposition"},{"key":"B81","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00005344-198811020-00013","article-title":"Verapamil pharmacodynamics and disposition in obese hypertensive patients","volume":"11","author":"Abernethy","year":"1988","journal-title":"J Cardiovasc Pharmacol"},{"key":"B82","first-page":"904","article-title":"Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration","volume":"266","author":"Abernethy","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"B83","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/sj.bjp.0707538","article-title":"Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers","volume":"153","author":"Hanafy","year":"2008","journal-title":"Br J Pharmacol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0091270008328099","article-title":"Influence of controlled rheumatoid arthritis on the action and disposition of verapamil: Focus on infliximab","volume":"49","author":"Ling","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/sj.bjp.0704067","article-title":"Drug-disease interactions: Reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat","volume":"133","author":"Kulmatycki","year":"2001","journal-title":"Br J Pharmacol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.2174\/13816128113199990550","article-title":"Action and disposition of the &beta;3-Agonist nebivolol in the presence of inflammation; an alternative to conventional &beta;1-Blockers","volume":"20","author":"Sanaee","year":"2014","journal-title":"Curr Pharm Des"},{"key":"B87","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.taap.2005.11.012","article-title":"Erythromycin potentiates PR interval prolonging effect of verapamil in the rat: A pharmacodynamic drug interaction","volume":"214","author":"Dakhel","year":"2006","journal-title":"Toxicol Appl Pharmacol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00228-018-2527-0","article-title":"Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients","volume":"74","author":"Tanaka","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"337","DOI":"10.18433\/j3d012","article-title":"Norepinephrine transporter is involved in down-regulation of \u03b21-adrenergic receptors caused by adjuvant arthritis","volume":"12","author":"Clements","year":"2009","journal-title":"J Pharm Pharm Sci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s00296-003-0357-5","article-title":"Heart rate variability in patients with rheumatoid arthritis","volume":"24","author":"Evrengul","year":"2004","journal-title":"Rheumatol Int"},{"key":"B91","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0304-3959(89)90177-2","article-title":"Altered autonomic function in patients with arthritis or with chronic myofascial pain","volume":"39","author":"Perry","year":"1989","journal-title":"Pain"},{"key":"B92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.2005.038059","article-title":"Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: Another example of uncoupling of response systems","volume":"65","author":"Harle","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1161\/01.hyp.0000225424.13138.5d","article-title":"Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans","volume":"48","author":"Mayer","year":"2006","journal-title":"Hypertension"},{"key":"B94","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","article-title":"Rheumatoid arthritis and cardiovascular disease","volume":"166","author":"Crowson","year":"2013","journal-title":"Am Heart J"},{"key":"B95","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.xphs.2017.09.020","article-title":"Drug-disease interaction: Effect of inflammation and nonsteroidal anti-inflammatory drugs on cytochrome P450 metabolites of arachidonic acid","volume":"107","author":"Aghazadeh-Habashi","year":"2018","journal-title":"J Pharm Sci"},{"key":"B96","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2310\/6650.2007.00020","article-title":"Intracardiac and intrarenal renin-angiotensin systems: Mechanisms of cardiovascular and renal effects","volume":"55","author":"Raizada","year":"2007","journal-title":"J Invest Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10753-010-9269-1","article-title":"Inflammation alters angiotensin converting enzymes (ACE and ACE-2) balance in rat heart","volume":"34","author":"Hanafy","year":"2011","journal-title":"Inflammation"},{"key":"B98","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10787-017-0344-1","article-title":"Cardiovascular effect of inflammation and nonsteroidal anti-inflammatory drugs on renin-angiotensin system in experimental arthritis","volume":"25","author":"Asghar","year":"2017","journal-title":"Inflammopharmacology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2125.1999.00902.x","article-title":"Pain-mediated altered absorption and metabolism of ibuprofen: An explanation for decreased serum enantiomer concentration after dental surgery","volume":"47","author":"Jamali","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/s2665-9913(20)30221-6","article-title":"Cardiovascular risk in inflammatory arthritis: Rheumatoid arthritis and gout","volume":"3","author":"Hansildaar","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1124\/dmd.118.082065","article-title":"Associations between cytokine levels and CYP3A4 phenotype in patients with rheumatoid arthritis","volume":"46","author":"Wollmann","year":"2018","journal-title":"Drug Metab Disposition"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e01177","DOI":"10.1128\/AAC.01177-20","article-title":"Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations","volume":"64","author":"Marzolini","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1002\/jcph.561","article-title":"Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach","volume":"55","author":"Zhuang","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/clpt.2011.35","article-title":"Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis","volume":"89","author":"Schmitt","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"B105","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1124\/dmd.117.078048","article-title":"The JAK1\/2 inhibitor ruxolitinib reverses interleukin-6-mediated suppression of drug-detoxifying proteins in cultured human hepatocytes","volume":"46","author":"Febvre-James","year":"2018","journal-title":"Drug Metab Disposition"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/bcp.13670","article-title":"Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis","volume":"84","author":"Khalilieh","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1177\/0091270006292163","article-title":"Drug-disease interactions: Losartan effect is not downregulated by rheumatoid arthritis","volume":"46","author":"Daneshtalab","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1177\/0091270003262951","article-title":"Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan","volume":"44","author":"Daneshtalab","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1592\/phco.2005.25.9.1213","article-title":"Protective effects of angiotensin II interruption: Evidence for antiinflammatory actions","volume":"25","author":"Dagenais","year":"2005","journal-title":"Pharmacotherapy"},{"key":"B110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3810\/pgm.2009.03.1974","article-title":"Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: An emerging strategy in hypertension therapy","volume":"121","author":"Oparil","year":"2009","journal-title":"Postgrad Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1021\/acs.molpharmaceut.9b00459","article-title":"Crohn's disease is associated with decreased CYP3A4 and P-glycoprotein protein expression","volume":"16","author":"Wilson","year":"2019","journal-title":"Mol Pharmaceutics"},{"key":"B112","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.gastro.2004.04.019","article-title":"Loss of detoxification in inflammatory bowel disease: Dysregulation of pregnane X receptor target genes","volume":"127","author":"Langmann","year":"2004","journal-title":"Gastroenterology"},{"key":"B113","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1254\/jphs.13141fp","article-title":"Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium\u2013induced colitis and its contribution to cyclosporine A blood concentrations","volume":"124","author":"Kawauchi","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1111\/jgh.12966","article-title":"Expression of hepatic cytochrome P450 in a mouse model of ulcerative colitis changes with pathological conditions","volume":"30","author":"Kusunoki","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1038\/sj.onc.1209377","article-title":"Cytochrome P450 pharmacogenetics and cancer","volume":"25","author":"Rodriguez-Antona","year":"2006","journal-title":"Oncogene"},{"key":"B116","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/jcph.1093","article-title":"Disease-drug interactions in inflammatory states via effects on CYP-mediated drug clearance","volume":"58","author":"Coutant","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cpt.128","article-title":"Understanding disease-drug interactions in cancer patients: Implications for dosing within the therapeutic window","volume":"98","author":"Coutant","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"B118","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/clpt.2014.143","article-title":"Cancer, inflammation, and therapy: Effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents","volume":"96","author":"Harvey","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"B119","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5414\/cpp46365","article-title":"Cytochrome P450 2C9 mediated metabolism in people with and without cancer","volume":"46","author":"Shord","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B120","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/sj.bjc.6600494","article-title":"Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: Implications for drug therapy","volume":"87","author":"Mart\u00ednez","year":"2002","journal-title":"Br J Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/gut.35.5.599","article-title":"Cytochrome P450 expression in oesophageal cancer","volume":"35","author":"Murray","year":"1994","journal-title":"Gut"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1111\/bph.14776","article-title":"Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation","volume":"176","author":"Trousil","year":"2019","journal-title":"Br J Pharmacol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-019-03905-3","article-title":"Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: Relevance for resistance to taxanes","volume":"84","author":"van Eijk","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"H2031","DOI":"10.1152\/ajpheart.01058.2004","article-title":"Adipokines: Molecular links between obesity and atheroslcerosis","volume":"288","author":"Lau","year":"2005","journal-title":"Am J Physiology-Heart Circulatory Physiol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"41","DOI":"10.18433\/jpps32488","article-title":"Piecing together human adult comparative pharmacokinetic trials and rodent studies: What happens to drug clearance in obesity?","volume":"25","author":"Brocks","year":"2022","journal-title":"J Pharm Pharm Sci"},{"key":"B126","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1210\/jcem.85.9.6839","article-title":"Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss*","volume":"85","author":"Bastard","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B127","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ygcen.2017.07.013","article-title":"A high-fat, high-protein diet attenuates the negative impact of casein-induced chronic inflammation on testicular steroidogenesis and sperm parameters in adult mice","volume":"252","author":"Zhao","year":"2017","journal-title":"Gen Comp Endocrinol"},{"key":"B128","first-page":"8","article-title":"Effects of obesity on the cytochrome P450 enzyme system","volume":"37","author":"Kotlyar","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B129","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/0926-6917(95)90059-4","article-title":"Defective expression of cytochrome P450 proteins in the liver of the genetically obese Zucker rat","volume":"293","author":"Irizar","year":"1995","journal-title":"Eur J Pharmacol Environ Toxicol Pharmacol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/0002-9149(84)90659-3","article-title":"Lidocaine disposition in obesity","volume":"53","author":"Abernethy","year":"1984","journal-title":"Am J Cardiol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cyto.2017.05.024","article-title":"Cytokines in immunogenic cell death: Applications for cancer immunotherapy","volume":"97","author":"Showalter","year":"2017","journal-title":"Cytokine"},{"key":"B132","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00467-008-1064-y","article-title":"Effect of obesity on response to cardiovascular drugs in pediatric patients with renal disease","volume":"24","author":"Hanafy","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.immuni.2013.10.001","article-title":"Systemic effects of inflammation on health during chronic HIV infection","volume":"39","author":"Deeks","year":"2013","journal-title":"Immunity"},{"key":"B134","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00228-009-0777-6","article-title":"Variability in drug metabolizing enzyme activity in HIV-infected patients","volume":"66","author":"Jones","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1128\/cdli.1.1.117-120.1994","article-title":"Differential elevation of circulating interleukin-1 beta, tumor necrosis factor alpha, and interleukin-6 in AIDS-associated cachectic states","volume":"1","author":"Belec","year":"1994","journal-title":"Clin Diagn Lab Immunol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3851\/imp3209","article-title":"Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s","volume":"23","author":"Venuto","year":"2018","journal-title":"Antivir Ther"},{"key":"B137","doi-asserted-by":"publisher","first-page":"259","DOI":"10.18433\/jpps31346","article-title":"Anti-inflammatory properties of drugs used to control COVID-19 and their effects on the renin-angiotensin system and angiotensin-converting enzyme-2","volume":"23","author":"Gilzad-Kohan","year":"2020","journal-title":"J Pharm Pharm Sci"},{"key":"B138","doi-asserted-by":"publisher","first-page":"58","DOI":"10.18433\/jpps31002","article-title":"Current drugs with potential for treatment of COVID-19: A literature review","volume":"23","author":"Md Insiat Islam","year":"2020","journal-title":"J Pharm Pharm Sci"},{"key":"B139","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2174\/138920012803341302","article-title":"Drug disposition in pathophysiological conditions","volume":"13","author":"Gandhi","year":"2012","journal-title":"Curr Drug Metab"},{"key":"B140","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.drudis.2011.02.014","article-title":"The effect of inflammation on drug metabolism: A focus on pediatrics","volume":"16","author":"Vet","year":"2011","journal-title":"Drug Discov Today"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.3201\/eid2608.201413","article-title":"Panton-valentine leukocidin-secreting Staphylococcus aureus pneumonia complicating COVID-19","volume":"26","author":"Duployez","year":"2020","journal-title":"Emerging Infect Dis"},{"key":"B142","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"key":"B143","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1017\/ice.2020.156","article-title":"Bacterial and fungal infections in COVID-19 patients: A matter of concern","volume":"41","author":"Zhou","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40779-020-00240-0","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil Med Res"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: The perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ"},{"key":"B147","doi-asserted-by":"publisher","first-page":"110033","DOI":"10.1016\/j.mehy.2020.110033","article-title":"Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms","volume":"144","author":"El-Ghiaty","year":"2020","journal-title":"Med Hypotheses"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"The Lancet"},{"key":"B149","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4049\/jimmunol.2000413","article-title":"COVID-19 as an acute inflammatory disease","volume":"205","author":"Manjili","year":"2020","journal-title":"J Immunol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/cts.12815","article-title":"What do we know about remdesivir drug interactions?","volume":"13","author":"Yang","year":"2020","journal-title":"Clin Transl Sci"},{"key":"B151","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1164\/rccm.201510-2114oc","article-title":"Inflammation and organ failure severely affect midazolam clearance in critically ill children","volume":"194","author":"Vet","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"B152","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/00003088-199835040-00004","article-title":"Drug disposition in cystic fibrosis","volume":"35","author":"Rey","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"B153","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12291-021-00963-4","article-title":"Clinical characteristics of paediatric hyperinflammatory syndrome in the era of corona virus disease 2019 (COVID-19)","volume":"36","author":"Basu","year":"2021","journal-title":"Indian J Clin Biochem"},{"key":"B154","doi-asserted-by":"publisher","first-page":"390","DOI":"10.18433\/jpps31931","article-title":"Losartan Inhibits SARS-CoV-2 Replication in vitro: Losartan promotes cell survival following SARS-CoV-2 infection in vitro","volume":"24","author":"Nejat","year":"2021","journal-title":"J Pharm Pharm Sci"},{"key":"B155","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fcvm.2018.00012","article-title":"Source of chronic inflammation in aging","volume":"5","author":"Sanada","year":"2018","journal-title":"Front Cardiovasc Med"},{"key":"B156","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/ageing\/10.2.73","article-title":"Drug response in the elderly--sensitivity and pharmacokinetic considerations","volume":"10","author":"Crooks","year":"1981","journal-title":"Age Ageing"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00228-015-1899-7","article-title":"Lower CYP2C9 activity in Turkish patients with behcet's disease compared to healthy subjects: A down-regulation due to inflammation?","volume":"71","author":"Goktas","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/ftd.0b013e3182666c62","article-title":"A puzzling case of increased serum clozapine levels in a patient with inflammation and infection","volume":"34","author":"Espnes","year":"2012","journal-title":"Ther Drug Monit"},{"key":"B159","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/s0924-977x(03)00042-7","article-title":"Toxic rise of clozapine plasma concentrations in relation to inflammation","volume":"13","author":"Haack","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"S489","DOI":"10.1016\/s0924-977x(13)70775-2","article-title":"P.3.d.052 prolonged delirious state after olanzapine pamoate injection as a consequence of pro-inflammatory cytokine secretion? A case report","volume":"23","author":"Sobanski","year":"2013","journal-title":"Eur Neuropsychopharmacol"}],"container-title":["Journal of Pharmacy &amp; Pharmaceutical Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/jpps.2023.11137\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T23:11:29Z","timestamp":1675638689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontierspartnerships.org\/articles\/10.3389\/jpps.2023.11137\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":160,"alternative-id":["10.3389\/jpps.2023.11137"],"URL":"https:\/\/doi.org\/10.3389\/jpps.2023.11137","relation":{},"ISSN":["1482-1826"],"issn-type":[{"value":"1482-1826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"article-number":"11137"}}